^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Testicular Seminoma

Related cancers:
2d
T cells in testicular germ cell tumors: new evidence of fundamental contributions by rare subsets. (PubMed, Br J Cancer)
Despite considerable heterogeneity between patients, T cell subtypes form a key part of the TGCT microenvironment. The novel finding of rare Treg and Tfh cells in human testis suggests their involvement in TGCT pathobiology, with implications for understanding tumor progression, to assess patients' prognosis, and as putative targets for personalized immunotherapy.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
6d
Gonadoblastoma: Clinicopathological study and literature review of 3 cases (PubMed, Zhonghua Nan Ke Xue)
Gonadoblastoma is a rare germ cell-sex cord stromal tumor, which is usually accompanied by gonadal hypoplasia. As a special subtype, dissecting gonadoblastoma will be easily confused with dysgerminoma/seminoma, but the prognosis is better. So we should improve the understanding of this subtype and avoid overdiagnosis.
Review • Journal
|
SOX9 (SRY-Box Transcription Factor 9) • FOXL2 (Forkhead Box L2)
10d
Familial syndromes associated with testicular and paratesticular neoplasms: a comprehensive review. (PubMed, Virchows Arch)
Additionally, an association between testicular sex cord stromal tumors and paratesticular sarcomas with Familial adenomatous polyposis syndrome and DICER1 syndrome, respectively, has been proposed as well. This review provides a comprehensive overview of the intricate relationship between familial syndromes and associated testicular and paratesticular tumors, shedding light on their clinicopathological and molecular characteristics.
Review • Journal
|
DICER1 (Dicer 1 Ribonuclease III)
28d
Expression of Immunotherapy Target PRAME in Cancer Correlates with Histone H3 Acetylation and Is Unrelated to Expression of Methylating (DMNT3A/3B) and Demethylating (TET1) Enzymes. (PubMed, J Clin Med)
However, histone acetylation may be one of the epigenetic mechanisms involved in PRAME regulation. Thus, the therapeutic combination of histone deacetylase inhibitors and PRAME immunotherapy merits further investigation.
Journal • IO biomarker • Epigenetic controller
|
DNMT3A (DNA methyltransferase 1) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
1m
SEMS: Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma (clinicaltrials.gov)
P=N/A, N=55, Active, not recruiting, University of Southern California | Phase classification: P2 --> P=N/A
Phase classification • Surgery • Metastases
|
AFP (Alpha-fetoprotein)
1m
Steroidogenic Acute Regulatory Protein Is a Useful Marker for Sex-Cord-Stroma Tumors and Normal and Neoplastic Adrenocortical Tissue. (PubMed, Arch Pathol Lab Med)
A comparison with preexisting Melan-A (a melanocyte antigen) data revealed that StAR was more often positive in adrenocortical neoplasms and in Leydig cell tumors while StAR (but not Melan-A) was negative in Sertoli cell tumors. Our data provide a comprehensive overview on the patterns of StAR immunostaining in human tumors and suggest a diagnostic utility of StAR immunohistochemistry for supporting a diagnosis of Leydig cell tumors or of normal or neoplastic adrenocortical tissue.
Journal • Stroma
|
MLANA (Melan-A) • STAR (Steroidogenic Acute Regulatory Protein)
1m
Utility of Circulating Tumor DNA in Patients with Different Stages of Testicular Cancer (AUA 2024)
ctDNA status was found to be correlated with the different stages of testicular cancer. ctDNA may be used for tailoring treatment protocols to patients with negative/mildly elevated serum tumor markers and for treatment escalation/deescalation. Prospective studies with larger cohorts are necessary to validate these initial results.
Clinical • Circulating tumor DNA
|
Signatera™
2ms
Influence of different pH milieu on the structure and function of human Aurora kinase B protein (AURK-B): Amalgamation of both spectroscopic and computational approach. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc)
More ordered conformation and compact structure was observed at this pH (pH 8.0) as compared to other pH values through molecular dynamics simulation studies (MDS). As AURK-B localizes itself in the intracellular compartment, this study may provide a clue about the role of different pH environments in enhancing cancer growth, proliferation, and invasion.
Journal
|
AURKB (Aurora Kinase B)
2ms
Multiple bronchial carcinoids associated with Cowden syndrome. (PubMed, Endocrine)
Our patient is the first published case of Cowden syndrome, associated with multifocal pulmonary carcinoids. Besides multiple endocrine neoplasia type 1, we propose Cowden syndrome as another hereditary condition predisposing to multiple pulmonary tumorlets and carcinoid tumours.
Journal
|
PTEN (Phosphatase and tensin homolog) • SSTR (Somatostatin Receptor)
|
PTEN mutation
3ms
Functional paraganglioma, an uncommon cause of seminoma metastasis, diagnostic and therapeutic management. (PubMed, Rev Esp Enferm Dig)
Postoperatively, hypertension and norepinephrine blood levels were normalized. The histological report surprisingly showed a Seminoma (positivity for PLAP, OCT ¾, c-kit, MDM2) and the surgical margins were free.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase)
3ms
Predictive tissue markers in testicular germ cell tumors: Immunohistochemical expression of MLH1 and REV-7 proteins. (PubMed, Int Urol Nephrol)
Loss of MLH1 expression was only found to be significantly associated with lower patients' age. Positive immunohistochemical REV-7 expression was significantly associated with various clinicopathological parameters, while it was also associated with significantly lower survival and greater hazard. REV-7 positive percentages were significantly higher in patients with chemoresistant disease. Our findings imply that immunohistochemical staining for REV-7 could potentially be used as a predictive tissue marker for TGCT tumors. Moreover, targeting of REV-7 protein, could represent a potential therapeutic strategy for chemoresistant TGCT cases. The implementation of well-designed studies on a larger scale is of utmost importance, in order to draw safer conclusions. Additional studies are needed so as to draw safer conclusions.
Journal
|
MLH1 (MutL homolog 1)
|
cisplatin
3ms
SMARCB1-Deficient Skull Base Chondrosarcoma with 12p Duplication Presenting as Somatic-Type Malignancy Arising from Metastatic Seminoma. (PubMed, Head Neck Pathol)
This case of STM chondrosarcoma demonstrated divergent immunophenotypic and molecular characteristics compared to "typical" examples of head and neck chondrosarcoma. High index of suspicion is advised regarding the diagnosis of lesions that present with otherwise typical histomorphology but unexpected immunohistochemical or molecular features.
Journal • Metastases
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
4ms
Frequent expression of CD45RO memory T cell marker as well as low to high expression of PD-1 and PD-L1 inhibitory molecules in seminoma and dysgerminoma. (PubMed, J Reprod Immunol)
The frequent infiltration of CD45RO, along with variable expression of PD-1 and PD-L1 on TILs and tumor cells, could impact the effectiveness of anti-tumor responses and immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 overexpression • PD-L1 underexpression • PD-1 expression
4ms
Changes in adhesion molecules: β-catenin, E-cadherin and Galectin-3 in cells of testicular seminoma. (PubMed, Front Oncol)
The expression of the Lgals3 gene encoding galectin-3 in seminomas was slightl higher in relation to the tissue unchanged by the carcinogenetic process. The results of the study suggest a significant role of β-catenin, E-cadherin and galectin-3 in the carcinogenesis of seminomas and may indicate new aspects of the patomechanism of seminomas formation, and thus time lead to better understand the biology of these tumors.
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • LGALS3 (Galectin 3)
|
CDH1 expression
4ms
Single-cell multi-omics analysis of human testicular germ cell tumor reveals its molecular features and microenvironment. (PubMed, Nat Commun)
Furthermore, we identify key pathways and genes that may facilitate seminoma disseminating beyond the seminiferous tubules. These findings advance our knowledge of seminoma tumorigenesis and produce a multi-omics atlas of in situ human seminoma microenvironment, which could help discover potential therapy targets for seminoma.
Journal
|
TFAP2A (Transcription Factor AP-2 Alpha) • TFAP2C (Transcription Factor AP-2 Gamma)
4ms
SWOG-S1823: A Study of miRNA 371 in Patients With Germ Cell Tumors (clinicaltrials.gov)
P=N/A, N=956, Recruiting, SWOG Cancer Research Network | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
Trial completion date • Trial primary completion date
|
AFP (Alpha-fetoprotein)
4ms
SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
P2, N=818, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> May 2026 | Trial primary completion date: Oct 2024 --> May 2026
Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
PD-L1 overexpression • PD-L1 amplification
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
4ms
Molecular and histopathological characterization of seminoma patients with highly elevated human chorionic gonadotropin levels in the serum. (PubMed, Virchows Arch)
In conclusion, excessively increased hCG serum levels can appear in patients with pure SEM. To explain detectable hCG serum levels, it is important to diagnose the subtype of a SEM with syncytiotrophoblasts.
Journal
|
SOX2 • PRAME (Preferentially Expressed Antigen In Melanoma) • SOX17 (SRY-Box Transcription Factor 17) • CDX2 (Caudal Type Homeobox 2) • SALL4 (Spalt Like Transcription Factor 4) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3) • TFAP2A (Transcription Factor AP-2 Alpha) • TFAP2C (Transcription Factor AP-2 Gamma) • TEAD4 (TEA Domain Transcription Factor 4)
4ms
Racial differences and predictors of outcomes in testicular cancer based on the National Cancer Database (NCDB). (ASCO-GU 2024)
Our analysis reveals some differences in survival trends with better survival in seminoma compared to non-seminoma, though Blacks and Hispanics have worse outcomes compared to Whites and Non-Hispanic Whites. This highlights the need for targeted efforts to bridge gaps in care.
4ms
Longitudinal tumor-informed ctDNA assay and patient outcomes in testicular cancer. (ASCO-GU 2024)
This is the first study that utilizes longitudinal tumor-informed ctDNA testing to assess patient outcomes and disease status. Our results suggest that tumor-informed ctDNA analysis may hold promise as a biomarker for EFS in patients with testicular cancer. As such, we developed the first-ever clinical nomogram that includes ctDNA status and other clinicopathological factors to stratify patient outcomes.
Clinical • Circulating tumor DNA
|
Signatera™
5ms
SPTBN1 Mediates the Cytoplasmic Constraint of PTTG1, Impairing Its Oncogenic Activity in Human Seminoma. (PubMed, Int J Mol Sci)
In human seminoma specimens, we found a strong PTTG1/SPTBN1 colocalization that decreases in areas with nuclear PTTG1 distribution. Overall, these results suggest that SPTBN1, along with PTTG1, is a potential prognostic factor useful in the clinical management of seminoma.
Journal
|
CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • SPTB (Spectrin Beta, Erythrocytic)
5ms
Genomic analysis of spermatocytic tumors demonstrates recurrent molecular alterations in cases with malignant clinical behavior. (PubMed, J Pathol)
© 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland
Journal
|
TP53 (Tumor protein P53) • RAS (Rat Sarcoma Virus)
|
TP53 mutation
5ms
Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates. (PubMed, Exp Hematol Oncol)
This study identified a nanobody-drug-conjugate targeting CXCR4 as a putative therapeutic option for GCT, i.e. seminoma and yolk-sac tumors. Furthermore, this study shed light on the functional role of the CXCR4 / CXCR7 / CXCL12-signaling cascade in GCT, demonstrating an important influence on proliferation and migration.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • ACKR3 (Atypical Chemokine Receptor 3)
5ms
Overexpression of SerpinB9 in non-seminomatous germ cell tumors. (PubMed, Med Mol Morphol)
These findings suggest that SerpinB9 contributes to the immune escape of testicular germ cell tumors. Targeting therapy for SerpinB9 might therefore be useful in immunotherapy for testicular germ cell tumors resistant to immune checkpoint inhibitors.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • GZMB (Granzyme B) • SERPINB9 (Serpin Family B Member 9)
|
CD8 positive
5ms
PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND (clinicaltrials.gov)
P2, N=60, Recruiting, Heinrich-Heine University, Duesseldorf
New P2 trial
|
cisplatin • carboplatin • etoposide IV • bleomycin
5ms
Oncogenic Gαq activates RhoJ through PDZ-RhoGEF. (PubMed, Int J Mol Sci)
In conclusion, we demonstrated that an oncogenic Gα mutant enables the PDZ-RhoGEF DH-PH module to recognize RhoJ, suggesting an allosteric mechanism by which this constitutively active GTPase stimulates RhoJ via PDZ-RhoGEF. These findings highlight PDZ-RhoGEF and RhoJ as potential targets in tumors driven by mutant Gαq.
Journal
|
RHOA (Ras homolog family member A) • CDC42 (Cell Division Cycle 42) • ARHGEF11 (Rho Guanine Nucleotide Exchange Factor 11)
5ms
Testicular cancer: new developments, molecular pathology, and current research keynote. (PubMed, Pathologie (Heidelb))
Non-pulmonary visceral metastases, high levels of the serum tumor markers alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG), and primary mediastinal non-seminoma are currently identified as determinants of poor prognosis. In addition, the presence of distinct microRNA profiles between seminomas and non-seminoma GCTs has opened up important perspectives in terms of noninvasive biomarkers that can be used in diagnosis and treatment monitoring.
Review • Journal
|
AFP (Alpha-fetoprotein)
5ms
Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy. (PubMed, Front Oncol)
Both histologies are exquisitely sensitive to platinum chemotherapy, and the combination of bleomycin, etoposide, and cisplatin (BEP) yields survival rates greater than 90%...We present available clinical trial data supporting de-escalation of chemotherapy treatment. Finally, we propose that future trials should enrol men, women, and children to benefit all patients regardless of age or sex.
Journal
|
TCF3 (Transcription Factor 3) • POU5F1 (POU Class 5 Homeobox 1) • NANOG (Nanog Homeobox)
|
KIT mutation • RAS mutation
|
cisplatin • carboplatin • etoposide IV • bleomycin
6ms
SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
P2, N=818, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
PD-L1 overexpression • PD-L1 amplification
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
6ms
Application of microRNAs in the diagnosis and monitoring of pediatric germ cell tumors: Kazakh experience. (PubMed, Pediatr Hematol Oncol)
Taking into consideration the high sensitivity and specificity, serum microRNAs 367,371,372,373,302d are of great interest for clinical use in malignant GCT. Significant expression of miR 375-3p was not detected either in malignant GCT or in teratomas.
Journal
|
AFP (Alpha-fetoprotein) • MIR375 (MicroRNA 375)
|
miR-375 expression
6ms
Extragonadal germ cell tumor: A case report and review of the literature (PubMed, Zhonghua Nan Ke Xue)
For patients with a history of cryptorchidism and tumors located in the central axis, special attention should be paid to physical examination of the testes, testicular ultrasonography, and determination of AFP and other indicators to identify gonadal tumor metastasis. And if so, radiotherapy and chemotherapy can be considered first to reduce surgical complications and achieve accurate management.
Review • Journal
|
AFP (Alpha-fetoprotein)
|
cisplatin • etoposide IV • bleomycin
6ms
Therapeutic effect of Heirong Kidney-Tonifying Granule on busulfan-induced dyszoospermia in model mice (PubMed, Zhonghua Nan Ke Xue)
HKTG improves the function of spermatogenic cells and increases sperm production in the testis tissue of mice by promoting meiosis.
Preclinical • Journal
|
SOX9 (SRY-Box Transcription Factor 9)
|
busulfan
6ms
Dysgerminoma ovarian germ cell tumours present high expressions of PDL-1 that associated with high tumour infiltrating lymphocytes and good patient prognosis (SITC 2023)
In addition, dysgerminoma/Seminoma have high PDL-1 expressions are associated with high genetic alterations and better prognosis compared to PDL-1 negative yolk Sac. Conclusions Our findings are likely to help improve knowledge about the potential benefits of ovarian cancer immunotherapy in specific subsets of germ cell tumour patients and risk factors for resistance that are mediated by the tumour microenvironment cells.
Clinical • Tumor-infiltrating lymphocyte • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 overexpression • PD-L1 negative
7ms
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs (clinicaltrials.gov)
P2, N=50, Recruiting, Jennifer King | Suspended --> Recruiting
Enrollment open
|
Cabometyx (cabozantinib tablet)
7ms
A Case of Testicular Cancer with Solitary Iliac Bone Metastasis (PubMed, Hinyokika Kiyo)
After one cycle of a bleomycin, etoposide and cisplatinum (BEP) regimen, he was referred to our hospital...Denosumab was also administered monthly...Because extirpation of the remaining mass would require resection of the left part of the pelvic bone with significant functional loss of the left limb, we performed close follow-up after an additional 2 courses of the etoposide and cisplatin regimen. The patient is currently alive without recurrence at 45 months after the last systemic chemotherapy.
Journal
|
AFP (Alpha-fetoprotein)
|
cisplatin • etoposide IV • Prolia (denosumab) • bleomycin
7ms
ESX1 gene as a potential candidate responsible for male infertility in nonobstructive azoospermia. (PubMed, Sci Rep)
Using RNA-seq, a network of over 50 genes potentially regulated by the ESX1 gene was determined. Finally, 6 genes, NANOG, CXCR4, RPS6KA5, CCND1, PDE1C, and LINC00662, participating in cell proliferation and differentiation were verified in azoospermic patients with and without a mutation in the ESX1 gene as well as in men with normal spermatogenesis, where inverse correlations in the expression levels of the observed genes were noted.
Journal
|
CCND1 (Cyclin D1) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • NANOG (Nanog Homeobox)
7ms
Proton Radiation Therapy for Stage IIA/IIB Testicular Seminoma. (PubMed, Int J Radiat Oncol Biol Phys)
In this case series, PBT for retroperitoneal and pelvic metastases in Stage IIA/IIB testicular seminoma was associated with oncologic efficacy with minimal toxicity. PBT reduces unnecessary dose to abdominal/pelvic organs compared to x-ray techniques, which is advantageous in young patients who have anticipated long-term survival. This is one of the few series reporting clinical outcomes of PBT in the management of seminoma. Randomized comparisons with x-ray approaches are impractical given the relatively low volume of patients receiving RT in modern seminoma management, so it is essential to report and track longitudinal outcomes across institutions to validate this approach.
Journal
7ms
Paradoxical Expression of R-10G-reactive Antigen in Human Testicular Embryonal Carcinoma. (PubMed, J Histochem Cytochem)
The percentages of R-10G-positive cells in these three groups varied with high statistical significance (p<0.001 for all combinations). These findings indicate that the R-10G-reactive antigen is preferentially expressed in human testicular EC tissues and, thus, could be used as a diagnostic marker for this malignancy.
Journal
7ms
Cytopathologic diagnosis of extragonadal germ cell tumors: A 10-year institutional review. (PubMed, Cancer Cytopathol)
Cytology can provide a reliable, accurate method for diagnosing EGGCTs. The practice of preoperative (neoadjuvant) chemotherapy places an extreme importance on the initial cytopathologic diagnosis because the majority of patients with follow-up resection in this series showed no residual tumor.
Review • Journal
7ms
Neither inguinoscrotal hernia nor hydrocele misunderstood giant testicular neoplasm. Case report and literature review. (PubMed, Ann Ital Chir)
This case report points out that there may be a poor correlation between clinical findings and pathophysiologic processes affecting scrotal structures. Additional radiological investigations, such as CT scan, could clarify and confirm the clinical scenario, improving the preoperative planning and surgical outcomes.
Review • Journal
7ms
Excellent survival in relapsed stage I testicular cancer. (PubMed, BMC Cancer)
GCC patients who relapse after initial CSI can be detected early by active surveillance and have an excellent survival.
Retrospective data • Journal
7ms
Clinical outcomes of de novo versus relapsed early metastatic testicular seminoma treated with contemporary radiation therapy. (PubMed, Int J Radiat Oncol Biol Phys)
In patients with CS-II seminoma treated with modern RT, there were no in-field recurrences. Presentation with de novo CS-II is associated with out-of-field recurrence. Subject to further larger-scale validation, our results suggest that compared to CS-II at time of relapse, de novo CS-II may portend more aggressive or micrometastatic disease beyond the retroperitoneum, raising the possibility of benefit from chemotherapy after radiation.
Clinical data • Journal • Metastases